TWI BIOTECHNOLOGY, INC.

ACTIVE

8F, No. 41, Lane 221, Gangqian Rd., 台湾 Taipei, 台湾省, Taiwanwww.twibiotech.comPublic

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

69.2%

Phase 1

23.1%

Phase 2/3

7.7%

Trial Status Distribution

Active, not recruiting

15.4%

Completed

69.2%

Not yet recruiting

7.7%

Terminated

7.7%

Clinical Trials

Trials sponsored by this organization (13)

A study to assess the efficacy and safety of Diacerein ointment in patients with bullous skin disease (EBS)

Phase 2/3

Not yet recruiting

interventional

Jul 2025100 participants

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Phase 2

Active, not recruiting

interventional

Apr 202480 participants

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

Phase 2

Completed

interventional

Mar 202493 participants

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Phase 1

Active, not recruiting

interventional

Dec 202387 participants

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

Phase 1

Completed

interventional

Oct 202213 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations

TWI BIOTECHNOLOGY, INC.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (13)

A study to assess the efficacy and safety of Diacerein ointment in patients with bullous skin disease (EBS)

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare

Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Approvals

News